REQUEST A DEMO
Total
USD $0.00
Search more companies

Scm Life Science Co.,Ltd. (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: Scm Life Science Co.,Ltd. Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company engaged in the research and development of medicines. The Company is engaged in the business of the development and production of cell therapy products, the agency testing of cell production and quality, adult stem cell consulting, cosmetics manufacturing, and hair growth protein manufacturing. The Company was established on July 2, 2014. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on June 17, 2020.

Headquarters
7-7, Gaetbeol-Ro 145Beon-Gil, Yeonsu-Gu
Incheon; Incheon;

Contact Details: Purchase the Scm Life Science Co.,Ltd. report to view the information.

Website: http://www.scmlifescience.com

Basic Information
Total Employees:
Purchase the Scm Life Science Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Scm Life Science Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Scm Life Science Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the Scm Life Science Co.,Ltd. report to view the information.
Incorporation Date:
July 02, 2014
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
에스씨엠생명과학㈜
Company Performance
Financial values in the chart are available after Scm Life Science Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
41.14%
Total operating revenue
N/A
Operating profit (EBIT)
49.26%
EBITDA
51.1%
Net Profit (Loss) for the Period
48.73%
Total assets
-42.66%
Total equity
-57.35%
Operating Profit Margin (ROS)
2286.24%
Net Profit Margin
2307.24%
Return on Equity (ROE)
-12.49%
Debt to Equity Ratio
20.8%
Quick Ratio
-9.7%
Cash Ratio
-10.35%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?